Pular para o conteúdo
Merck
Todas as fotos(1)

Documentos Principais

SML0038

Sigma-Aldrich

Fluvastatin sodium hydrate

≥98% (HPLC)

Sinônimo(s):

(±)-(3R*,5S*,6E)-7-[3-(4-Fluorophenyl)-1-(1-methyethyl)-1H-indol-2-yl]-3,5-dihydroxy-6-heptenoic acid sodium salt hydrate

Faça loginpara ver os preços organizacionais e de contrato

Selecione um tamanho

10 MG
R$ 684,00
50 MG
R$ 2.763,00

R$ 684,00


Disponível para enviar em15 de abril de 2025Detalhes


Solicite uma grande encomenda

Selecione um tamanho

Alterar visualização
10 MG
R$ 684,00
50 MG
R$ 2.763,00

About This Item

Fórmula empírica (Notação de Hill):
C24H25FNO4 · Na · xH2O
Número CAS:
Peso molecular:
433.45 (anhydrous basis)
Número MDL:
Código UNSPSC:
12352204
ID de substância PubChem:
NACRES:
NA.77

R$ 684,00


Disponível para enviar em15 de abril de 2025Detalhes


Solicite uma grande encomenda

Ensaio

≥98% (HPLC)

Formulário

powder

condição de armazenamento

desiccated

cor

white to tan

solubilidade

H2O: ≥9 mg/mL

originador

Novartis

temperatura de armazenamento

2-8°C

cadeia de caracteres SMILES

O.[Na+].CC(C)n1c(\C=C\[C@@H](O)C[C@@H](O)CC([O-])=O)c(-c2ccc(F)cc2)c3ccccc13

InChI

1S/C24H26FNO4.Na.H2O/c1-15(2)26-21-6-4-3-5-20(21)24(16-7-9-17(25)10-8-16)22(26)12-11-18(27)13-19(28)14-23(29)30;;/h3-12,15,18-19,27-28H,13-14H2,1-2H3,(H,29,30);;1H2/q;+1;/p-1/b12-11+;;/t18-,19-;;/m1../s1

chave InChI

KKEMYLLTGGQWCE-PMRANXHDSA-M

Aplicação

Fluvastatin sodium hydrate has been used:
  • to examine its effect on β -glucan-induced training on immunity[1]
  • to investigate the effect of statins on the number of uncoupling protein 1 (UCP1)+ cells[2]
  • to determine its effect on insulin degrading enzyme (IDE) secretion from astrocytes[3]
  • to treat and study its effect on human umbilical vein endothelial cells (HUVECs) in vitro[4]

Fluvastatin sodium hydrate has been used:
  • to test its anti-hepatitis C virus (HCV) activity[5]
  • as a cholesterol inhibitor[6]
  • to study its effects on β-glucan-induced monocyte immune training[1]

Ações bioquímicas/fisiológicas

Fluvastatin has antifungal activity.[7]
Fluvastatin is a competitive inhibitor of hydroxymethylglutaryl-coenzyme A (HMG-CoA) reductase, the enzyme that catalyzes the conversion of HMG-CoA to mevalonic acid, the rate-limiting step in cholesterol biosynthesis. Fluvastatin is antilipemic and is used to reduce plasma cholesterol levels and prevent cardiovascular disease.

Características e benefícios

This compound was developed by Novartis. To browse the list of other pharma-developed compounds and Approved Drugs/Drug Candidates, click here.

Código de classe de armazenamento

11 - Combustible Solids

Classe de risco de água (WGK)

WGK 3

Ponto de fulgor (°F)

Not applicable

Ponto de fulgor (°C)

Not applicable


Escolha uma das versões mais recentes:

Certificados de análise (COA)

Lot/Batch Number

Não está vendo a versão correta?

Se precisar de uma versão específica, você pode procurar um certificado específico pelo número do lote ou da remessa.

Já possui este produto?

Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.

Visite a Biblioteca de Documentos

Os clientes também visualizaram

Slide 1 of 5

1 of 5

Mevastatin ≥98% (HPLC), powder or crystals

Sigma-Aldrich

M2537

Mevastatin

Cefaclor

Sigma-Aldrich

C6895

Cefaclor

Simvastatin analytical standard

Supelco

38956

Simvastatin

Avasimibe: a novel hepatitis C virus inhibitor that targets the assembly of infectious viral particles
Hu L, et al.
Antiviral Research, 148, 5-14 (2017)
Kazuho Sakamoto et al.
The Journal of pharmacology and experimental therapeutics, 338(1), 62-69 (2011-04-07)
HMG-CoA reductase inhibitor statins are used for the treatment of hypercholesterolemia. However, statins have adverse effects on skeletal muscles with unknown mechanism. We have reported previously that fluvastatin induced vacuolation and cell death in rat skeletal myofibers by depleting geranylgeranylpyrophosphate
Mojca Lunder et al.
Atherosclerosis, 215(2), 446-451 (2011-02-09)
Early arterial wall changes are already present in the apparently healthy, middle-aged population and continuously progress with age. The aim of our study was to investigate whether 30 days low-dose fluvastatin treatment could improve and reverse these arterial changes that
Metabolic induction of trained immunity through the mevalonate pathway
Bekkering S, et al.
Cell, 172(1-2), 135-146 (2018)
Current Cardiovascular Drugs (2005)

Artigos

Discover Bioactive Small Molecules for Lipid Signaling Research

Questions

Reviews

No rating value

Active Filters

Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.

Entre em contato com a assistência técnica